FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113530759> ?p ?o ?g. }

• W2113530759 endingPage "426" @default.
• W2113530759 startingPage "417" @default.
• W2113530759 abstract "Whether to continue oral anticoagulant therapy beyond 6 months after an unprovoked venous thromboembolism is controversial. We sought to determine clinical predictors to identify patients who are at low risk of recurrent venous thromboembolism who could safely discontinue oral anticoagulants.In a multicentre prospective cohort study, 646 participants with a first, unprovoked major venous thromboembolism were enrolled over a 4-year period. Of these, 600 participants completed a mean 18-month follow-up in September 2006. We collected data for 69 potential predictors of recurrent venous thromboembolism while patients were taking oral anticoagulation therapy (5-7 months after initiation). During follow-up after discontinuing oral anticoagulation therapy, all episodes of suspected recurrent venous thromboembolism were independently adjudicated. We performed a multivariable analysis of predictor variables (p < 0.10) with high interobserver reliability to derive a clinical decision rule.We identified 91 confirmed episodes of recurrent venous thromboembolism during follow-up after discontinuing oral anticoagulation therapy (annual risk 9.3%, 95% CI 7.7%-11.3%). Men had a 13.7% (95% CI 10.8%-17.0%) annual risk. There was no combination of clinical predictors that satisfied our criteria for identifying a low-risk subgroup of men. Fifty-two percent of women had 0 or 1 of the following characteristics: hyperpigmentation, edema or redness of either leg; D-dimer > or = 250 microg/L while taking warfarin; body mass index > or = 30 kg/m(2); or age > or = 65 years. These women had an annual risk of 1.6% (95% CI 0.3%-4.6%). Women who had 2 or more of these findings had an annual risk of 14.1% (95% CI 10.9%-17.3%).Women with 0 or 1 risk factor may safely discontinue oral anticoagulant therapy after 6 months of therapy following a first unprovoked venous thromboembolism. This criterion does not apply to men." @default.
• W2113530759 created "2016-06-24" @default.
• W2113530759 creator A5007444643 @default.
• W2113530759 creator A5018213701 @default.
• W2113530759 creator A5018260212 @default.
• W2113530759 creator A5026942789 @default.
• W2113530759 creator A5032289413 @default.
• W2113530759 creator A5041012345 @default.
• W2113530759 creator A5041929525 @default.
• W2113530759 creator A5051047770 @default.
• W2113530759 creator A5062867494 @default.
• W2113530759 creator A5071739915 @default.
• W2113530759 creator A5077857331 @default.
• W2113530759 creator A5077997051 @default.
• W2113530759 creator A5079941141 @default.
• W2113530759 creator A5080411779 @default.
• W2113530759 date "2008-07-17" @default.
• W2113530759 modified "2023-10-16" @default.
• W2113530759 title "Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy" @default.
• W2113530759 cites W1723148185 @default.
• W2113530759 cites W1752822397 @default.
• W2113530759 cites W1777100975 @default.
• W2113530759 cites W1978280229 @default.
• W2113530759 cites W1998093012 @default.
• W2113530759 cites W2012301002 @default.
• W2113530759 cites W2012519169 @default.
• W2113530759 cites W2014569258 @default.
• W2113530759 cites W2022713742 @default.
• W2113530759 cites W2031127066 @default.
• W2113530759 cites W2042142238 @default.
• W2113530759 cites W2047986798 @default.
• W2113530759 cites W2054515228 @default.
• W2113530759 cites W2067741035 @default.
• W2113530759 cites W2073192852 @default.
• W2113530759 cites W2087646765 @default.
• W2113530759 cites W2089335489 @default.
• W2113530759 cites W2102778065 @default.
• W2113530759 cites W2110891636 @default.
• W2113530759 cites W2112757583 @default.
• W2113530759 cites W2112964278 @default.
• W2113530759 cites W2129839379 @default.
• W2113530759 cites W2134355273 @default.
• W2113530759 cites W2138845401 @default.
• W2113530759 cites W2141045095 @default.
• W2113530759 cites W2160362541 @default.
• W2113530759 cites W2167728254 @default.
• W2113530759 cites W2169472792 @default.
• W2113530759 cites W2261511218 @default.
• W2113530759 cites W2331935930 @default.
• W2113530759 cites W2332640098 @default.
• W2113530759 cites W2337281790 @default.
• W2113530759 cites W2413750029 @default.
• W2113530759 cites W2568332688 @default.
• W2113530759 cites W2569281637 @default.
• W2113530759 cites W3021544616 @default.
• W2113530759 cites W2040937833 @default.
• W2113530759 cites W2419417493 @default.
• W2113530759 doi "https://doi.org/10.1503/cmaj.080493" @default.
• W2113530759 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2518177" @default.
• W2113530759 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18725614" @default.
• W2113530759 hasPublicationYear "2008" @default.
• W2113530759 type Work @default.
• W2113530759 sameAs 2113530759 @default.
• W2113530759 citedByCount "492" @default.
• W2113530759 countsByYear W21135307592012 @default.
• W2113530759 countsByYear W21135307592013 @default.
• W2113530759 countsByYear W21135307592014 @default.
• W2113530759 countsByYear W21135307592015 @default.
• W2113530759 countsByYear W21135307592016 @default.
• W2113530759 countsByYear W21135307592017 @default.
• W2113530759 countsByYear W21135307592018 @default.
• W2113530759 countsByYear W21135307592019 @default.
• W2113530759 countsByYear W21135307592020 @default.
• W2113530759 countsByYear W21135307592021 @default.
• W2113530759 countsByYear W21135307592022 @default.
• W2113530759 countsByYear W21135307592023 @default.
• W2113530759 crossrefType "journal-article" @default.
• W2113530759 hasAuthorship W2113530759A5007444643 @default.
• W2113530759 hasAuthorship W2113530759A5018213701 @default.
• W2113530759 hasAuthorship W2113530759A5018260212 @default.
• W2113530759 hasAuthorship W2113530759A5026942789 @default.
• W2113530759 hasAuthorship W2113530759A5032289413 @default.
• W2113530759 hasAuthorship W2113530759A5041012345 @default.
• W2113530759 hasAuthorship W2113530759A5041929525 @default.
• W2113530759 hasAuthorship W2113530759A5051047770 @default.
• W2113530759 hasAuthorship W2113530759A5062867494 @default.
• W2113530759 hasAuthorship W2113530759A5071739915 @default.
• W2113530759 hasAuthorship W2113530759A5077857331 @default.
• W2113530759 hasAuthorship W2113530759A5077997051 @default.
• W2113530759 hasAuthorship W2113530759A5079941141 @default.
• W2113530759 hasAuthorship W2113530759A5080411779 @default.
• W2113530759 hasBestOaLocation W21135307591 @default.
• W2113530759 hasConcept C126322002 @default.
• W2113530759 hasConcept C141071460 @default.
• W2113530759 hasConcept C188816634 @default.
• W2113530759 hasConcept C201903717 @default.
• W2113530759 hasConcept C2776265017 @default.
• W2113530759 hasConcept C2776301958 @default.

• next